Biogen (BIIB)

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

Company profile

Josephine Price
Fiscal year end
Former names
Biogen Foundation Inc. • Biogen MA Inc. • Biogen Realty Corporation • Biogen Realty Limited Partnership • Biogen U.S. Corporation • Biogen U.S. Limited Partnership • Biogen (RTP) Realty LLC • Biogen Chesapeake LLC • Biogen Digital Health Inc. • Biogen Holding I LLC ...
IRS number

BIIB stock data


20 Jul 22
19 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Aug 22 Nicole Murphy Common Stock Payment of exercise Dispose F No No 209.26 243 50.85K 2,676.29
1 Aug 22 Nicole Murphy Common Stock Option exercise Acquire M No No 0 825 0 2,919.29
1 Aug 22 Nicole Murphy Common Stock Payment of exercise Dispose F No No 209.26 76 15.9K 2,094.29
1 Aug 22 Nicole Murphy Common Stock Option exercise Acquire M No No 0 255 0 2,170.29
1 Aug 22 Nicole Murphy RSU Common Stock Option exercise Dispose M No No 0 825 0 0
1 Aug 22 Nicole Murphy RSU Common Stock Option exercise Dispose M No No 0 255 0 0
1 Aug 22 Nicole Murphy RSU Common Stock Other Dispose J No No 0 299 0 255
1 Jul 22 Rachid Izzar Common Stock Payment of exercise Dispose F No No 210.63 148 31.17K 2,110
1 Jul 22 Rachid Izzar Common Stock Option exercise Acquire M No No 0 504 0 2,258
1 Jul 22 Rachid Izzar RSU Common Stock Option exercise Dispose M No No 0 504 0 504
81.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 877 920 -4.7%
Opened positions 72 79 -8.9%
Closed positions 115 136 -15.4%
Increased positions 280 307 -8.8%
Reduced positions 339 379 -10.6%
13F shares Current Prev Q Change
Total value 24.13B 25.44B -5.2%
Total shares 117.97M 120.87M -2.4%
Total puts 3.49M 3.39M +2.9%
Total calls 3.14M 2.86M +9.8%
Total put/call ratio 1.1 1.2 -6.3%
Largest owners Shares Value Change
Primecap Management 15.73M $3.21B -0.7%
BLK Blackrock 14.46M $2.95B +2.4%
Vanguard 11.86M $2.42B +1.2%
STT State Street 6.88M $1.4B -4.6%
Wellington Management 6.29M $1.28B +0.6%
Geode Capital Management 3.25M $660.83M +15.6%
JPM JPMorgan Chase & Co. 1.98M $402.8M -9.2%
Clearbridge Advisors 1.97M $401.19M -21.7%
NTRS Northern Trust 1.71M $348.65M +1.4%
DB Deutsche Bank AG - Registered Shares 1.67M $339.95M +15.8%
Largest transactions Shares Bought/sold Change
LGEN Legal & General 0 -1.44M EXIT
Southeastern Asset Management 0 -842.96K EXIT
MNGPF Man 0 -820.81K EXIT
FMR 1.03M +638.2K +164.5%
Intech Investment Management 571.77K +571.77K NEW
Clearbridge Advisors 1.97M -543.78K -21.7%
Renaissance Technologies 1.55M +501.8K +48.1%
Parametric Portfolio Associates 0 -495K EXIT
American Century Companies 428.1K -451.7K -51.3%
Geode Capital Management 3.25M +438.86K +15.6%

Financial report summary

  • We are substantially dependent on revenue from our products.
  • Our long-term success depends upon the successful development of new products and additional indications for our existing products.
  • If we fail to compete effectively, our business and market position would suffer.
  • We depend on relationships with collaborators, joint venture partners and other third-parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.
  • Our results of operations may be adversely affected by current and potential future healthcare reforms.
  • Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.
  • If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed.
  • Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.
  • Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.
  • Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.
  • The illegal distribution and sale by third-parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.
  • The increasing use of social media platforms presents new risks and challenges.
  • A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.
  • Management and other personnel changes may disrupt our operations, and we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company.
  • If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.
  • Our sales and operations are subject to the risks of doing business internationally.
  • We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.
  • Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.
  • The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.
  • Our operating results are subject to significant fluctuations.
  • Our investments in properties may not be fully realized.
  • Our investment portfolio is subject to market, interest and credit risk that may reduce its value.
  • There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.
  • We may not be able to access the capital and credit markets on terms that are favorable to us.
  • Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business.
  • Some of our collaboration agreements contain change in control provisions that may discourage a third-party from attempting to acquire us.
  • Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.
  • Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.
Management Discussion
  • Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.
  • Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18,

Content analysis

H.S. sophomore Good
New words: admission, certiorari, CLE, closure, conclusion, derecognized, divest, divestment, entrant, hand, lieu, nonclinical, PDUFA, principle, priority, procuring, readout, reorganization, resolve, SKYLARK, sooner, TBA, treasury, unsettled, User, wider, women, writ
Removed: accrual, amortize, community, immaterial, intervention, pursuing, reimburse, upheld


Method for Treating Subjects Suffering from Central Nervous System Contusions
21 Jul 22
Methods of inhibiting expansion of cerebral contusion, inhibiting secondary hemorrhage and capillary fragmentation in the brain, reducing pericontusional edema and hemorrhage size in the brain, decreasing water content in a CNS tissue, inhibiting disruption of the blood-brain barrier, inhibiting CNS contusion progression and improving post-contusion motor function, inhibiting microvascular impairment caused by endothelial cell swelling and fragmentation, inhibiting extravasation of blood into the brain parenchyma of a subject, inhibiting endothelial cell breakdown in a brain tissue, inhibiting extravasation of endovascular fluids into the brain's interstitium, decreasing vasogenic edema as measured by T2 flair magnetic resonance imaging, and decreasing matrix metalloprotease concentration in a CNS tissue, by administering a SUR1-TRPM4 channel inhibitor alone or in combination with one or more drugs or agents.
Pharmaceutical Composition Containing Dimethyl Fumarate for Administration at a Low Daily Dose
2 Jun 22
The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF), More specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.
Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
24 May 22
The present disclosure provides methods of assaying for antibody-dependent cell-mediated phagocytosis (ADCP).
Methods of Treating Injuries or Conditions Related to CNS Edema
28 Apr 22
The present technology is related to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors.
Methods of medical treatment with SUR1-TRPM4 channel inhibitors
19 Apr 22
A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof.